Artificial Cervical Intervertebral Disc Market is projected to reach US$ 4.37529 billion by 2028 from an estimated value of US$ 1.62166 billion in 2022; it is estimated to grow at a CAGR of 18.0% from 2022 to 2028.
New York, July 25, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on "Artificial Cervical Intervertebral Disc Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Material, End User, and Geography," the market Increasing cases of cervical injuries and a rise in the aging population drive the market growth. However, the high cost of cervical intervertebral disc surgeries hampers the artificial cervical intervertebral disc market growth.
Request Sample PDF Copy of Artificial Cervical Intervertebral Disc Market Size - COVID-19 Impact and Global Analysis with Strategic Developments at: https://www.theinsightpartners.com/sample/TIPRE00023194/
Artificial Cervical Intervertebral Disc Market Report Scope & Strategic Insights:
No. of Charts & Figures
Material, End User, and Geography
North America; Europe; Asia Pacific; Latin America; MEA
US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Artificial Cervical Intervertebral Disc Market: Competitive Landscape and Key Developments
Zimmer Biomet Holdings, Inc.; Globus Medical, Inc.; Centinel Spine, LLC; Synergy Spine Solutions, Inc.; B. Braun Melsugen AG; Aditus Medical; AxioMed LLC; NuVasive, Inc.; Medtronic; and Orthofix Medical, Inc. are among the leading companies operating in the artificial cervical intervertebral disc market.
Inquiry Before Purchase: https://www.theinsightpartners.com/inquiry/TIPRE00023194/
Companies operating in the artificial cervical intervertebral disc market implement various organic developments that lead to dynamic improvements in the market. Various organic growth strategies such as product launch and product development propel the market growth. Several companies are implementing numerous inorganic strategies, such as partnerships, and mergers and acquisitions.
In February 2022, AxioMed moved closer toward achieving US FDA approval of its viscoelastic total disc replacement, after submitting PMA module II for the completion of an IDE clinical study. According to AxioMed, the clinical data supporting the device is strong with no reported device-related failures or revisions, and rare cases of heterotopic bone formation.
In September 2021, more than 60,000 M6-C artificial cervical discs of Orthofix Medical were implanted worldwide. The implant is a next-generation artificial disc designed to mimic the natural motion of a native disc. Developed to replace an intervertebral disc damaged by cervical disc degeneration, the M6-C disc is indicated as an alternative to cervical fusion. After the prior approval for distribution under the CE Mark in the European Union and other international geographies, the M6-C disc received an FDA approval in 2019.
In February 2021, NuVasive, Inc., acquired Simplify Medical, the developer of the Simplify Cervical Artificial Disc (Simplify Disc) for cTDR. The acquisition of Simplify Medical added the most clinically effective cTDR technology and distinguished NuVasive’s cervical portfolio in the market. The cervical segment of the global spine market represents an opportunity with an estimated worth of US$ 2.6 billion, and the company has been well-positioned to expand its reach with the addition of the Simplify Disc to its C360 portfolio.
Have a question? Speak to Research Analyst: https://www.theinsightpartners.com/speak-to-analyst/TIPRE00023194
Companies in the artificial cervical intervertebral disc market are undertaking many research and development activities to introduce innovative products. New replacement therapies enable the adoption of advanced technologies, strengthening the procedural outcomes. For instance, in April 2021, US Food and Drug Administration (FDA approved) NuVasive Simplify Cervical Artificial Disc for two-level cervical total disc replacement (cTDR). Additionally, in August 2020, Orthofix Medical Inc., a global medical device company focused on musculoskeletal products and therapies, received the US FDA approval for its M6-C artificial cervical disc offered for treating the patients suffering from cervical disc degeneration. The M6-C artificial cervical disc, a next-generation artificial disc, is developed to replace the damaged intervertebral disc, which also restores physiologic motion to the spine. Moreover, in May 2018, Zimmer Biomet received approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for its Mobi-C Cervical Disc for cervical total disc replacement (cTDR). Mobi-C is the first cervical disc prosthesis approved by the US FDA to reconstruct a cervical disc at one and two levels (C3-C7). Such robust developments are likely to reshape the artificial cervical intervertebral disc market during the forecast period.
In North America, the US holds a significant share of the artificial cervical intervertebral disc market. The market growth in the US is primarily driven by increasing aging population in the US, growing prevalence of cervical degenerative disc disease, and surging number of spine injuries. As per the Fact Sheet: Aging in the United States, the number of individuals in aged 65 and older in the US, is estimated to reach ~95 million by 2060 from 52 million in 2018, and its share in the total population is likely to spike up to 23% from 16%. Further, it is estimated that ~5 million adults in the US are disabled by spine-related disorders; however, candidates for spinal surgery account for a tiny portion of these people. These factors are likely to boost the growth of artificial cervical intervertebral disc market in the US.
Avail Lucrative DISCOUNTS on “Artificial Cervical Intervertebral Disc Market” Research Study: https://www.theinsightpartners.com/discount/TIPRE00023194/
The artificial cervical intervertebral disc market players are adopting various organic and inorganic strategies for market development. For instance, in April 2022, the data of the NuVasive Simplify Cervical Disc (Simplify Disc) two-level US FDA Investigational Device Exemption (IDE) study was published in the Journal of Neurosurgery: Spine. The data will be utilized in the device's FDA pre-market application for two-level indication approval, which was earlier approved in April 2021
Artificial Cervical Intervertebral Disc Market: Segmental Overview
Based on end user, the artificial cervical intervertebral disc market is segmented into hospitals, ambulatory surgical centers, and others. In 2022, the hospitals segment is estimated to hold the largest share of the market. However, the ambulatory surgical centers segment is expected to experience the highest CAGR during 2022–2028. Ambulatory surgical centers offer cost-effective services in a convenient environment, which is less stressful than many hospitals. They also offer one day procedures, in advanced operating rooms, under the care of highly skilled healthcare professionals. Thus, owing high quality care, cost-effective treatments, and expanding access are likely to favor the market growth of this segment.
Directly Purchase Premium Copy of Artificial Cervical Intervertebral Disc Market Growth Report (2022-2028) at: https://www.theinsightpartners.com/buy/TIPRE00023194/
Browse Adjoining Reports:
Artificial Disc Replacement Systems Market Forecast to 2028 - Covid-19 Impact and Global Analysis - by Disc Type (Composite, Elastic, Mechanical, Others); Location ( Cervical Discs Replacement, Lumbar Disc Replacement ); Material ( Metal, Biopolymer, Mixed, Others ) and Geography
Prestige Cervical Disc Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Metal-on-metal, Metal-on-polymer, Others); End-user (Hospital, Clinic, Others) and Geography
Lumbar Artificial Disc Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Material (Cobalt-chrome Alloys, Titanium Alloys, Stainless Steels, Polyethylene, Polyurethane, Ceramics); End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers), and Geography
Artificial Disc Market Forecast to 2028 - Covid-19 Impact and Global Analysis - By Type (Cervical, Lumbar); Material (Metal on Biopolymer, Metal on Metal Artificial Disc); End User (Hospitals, Clinics, Homecare Settings, Others)
Disc Prostheses Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Lumbar Disc, Cervical Disc); Application (Metal-on-polymer, Metal-on-metal, Others); and Geography
Motion Preservation Devices Market Forecast to 2028 - Covid-19 Impact and Global Analysis - by Product (Nuclear disc prostheses devices, Annulus repair devices, Artificial discs, Dynamic stabilization devices); Procedure Type (Minimally invasive surgery, Open spine surgery) and Geography
Cervical Vertebra Tractor Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Type (Portable, Mechanical); Application (Household, Hospital, Other)
About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us: If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi E-mail: sales@theinsightpartners.com Phone: +1-646-491-9876 Press Release: https://www.theinsightpartners.com/pr/artificial-cervical-intervertebral-disc-market
SIGA Technologies, maker of the only available monkeypox treatment, is working to ramp up manufacturing for broader global distribution.
We just can't get a break from COVID. While things were inching closer towards normalcy, cases are rising again thanks to the latest dominant variant BA.5, which experts say is the most contagious COVID strain yet. Although the virus affects everyone differently, there are symptoms to watch out for that indicate you've had COVID and Eat This, Not That! Health spoke with Dr. Mark Fischer, Regional Medical Director at International SOS who explains what to know about BA.5 and symptoms to watch out
Whether you're nursing a cold or need a quick and easy lunch, soup is the one food that practically everyone has in their pantry. No matter much or little you know about cooking, being able to grab your can opener or tear into a packet for a reliably good meal is a convenience that's too good for most to pass up—especially if you haven't had time to make it to the grocery store for fresh ingredients lately. But now, the Food&Drug Administration (FDA) is warning consumers that one soup that may b
A Copenhagen company worked for nearly two decades to develop a vaccine and only six governments bought it. Bavarian Nordic A/S is the world’s sole supplier of a licensed vaccine for monkeypox. The World Health Organization in recent days declared the disease a public health emergency of international concern, the first time the group has issued that designation since the early days of the Covid-19 pandemic.
The Biden administration said it would spend $1.74 billion to buy 66 million doses of Moderna updated Covid-19 vaccine, as well as the option to purchase up to 234 million additional doses, as part of a fall booster campaign. The deal Friday, which follows an agreement to buy 105 million doses of updated vaccines from Pfizer and partner BioNTech SE is expected to give the federal government enough shots for a booster push as early as September. Under the latest deal, the U.S. government has the option to buy up to an additional 234 million doses from Moderna.
The highly contagious BA.5 subvariant is causing a nationwide spike in cases, and experts believe the numbers might actually be higher thanks to at-home testing. But even without accurate data, there is no doubt a surge is happening. "You don't have to count every raindrop to know it's raining," says Dr. Joseph Kanter, Louisiana's state health officer and medical director. "And it's pouring right now." Here are five signs of BA.5 that are easy to miss, according to experts. Read on—and to ensure
We all know the feeling—standing there in the bread aisle at the grocery store, craving a delicious sandwich or slice of toast, while simultaneously telling ourselves that we can't buy any bread because it's "unhealthy."But why do we so often force ourselves to avoid bread when in reality bread isn't the enemy? We've been told for so long that in order to be healthy we have to avoid carbs, but giving up bread completely may mean you'll lose out on valuable nutrients.The main distinction to note
A federal court ruling has dealt a blow to Bausch Health by appearing to clear the way for generic competition for the company’s drug Xifaxan. Bausch Health stock (ticker: BHC) plummeted more than 50% Thursday morning on the news, and trading of the shares was halted. In 2020, Bausch Health Ireland and Salix Pharmaceuticals sued Norwich Pharmaceuticals in 2020 for patent infringement, regarding Norwich’s plans to bring a generic version of Xifaxan to market before its patents had expired, according to a Bloomberg Law report.
Monkeypox has spread across multiple countries, including the U.S., where the Centers for Disease Control and Prevention (CDC) has confirmed almost 5,000 cases since May. While reminiscent of the beginning of the COVID-19 pandemic, this viral disease spreads differently. We all remember masking up, wearing gloves, and waiting in line to get into the grocery store in 2020, but will we have to do that again because of this virus?Experts at the CDC and others say monkeypox spreads mostly through cl
The 300 vaccines that were allocated for DeKalb County are already spoken for.
We are in an epidemic of stress right now, and ashwagandha is an adaptogenic that helps our bodies become more resilient to stress, says Robin Foroutan, RDN.
AstraZeneca's Covid-19 antibody drug slashes the risk of new variants emerging, the company said, as Britain faces mounting pressure to follow other Western nations in ordering doses.
U.S. regulators said Friday they are no longer considering authorizing a second COVID-19 booster shot for all adults under 50 this summer, focusing instead on revamped vaccines for the fall that will target the newest viral subvariants. Pfizer and Moderna expect to have updated versions of their shots available as early as September, the Food and Drug Administration said in a statement. The announcement means the U.S. won’t pursue a summer round of boosters using the current vaccines for adults under 50, as some Biden administration officials and outside experts previously suggested.
Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?
The sharpest opinions on the debate from around the web
With growing concerns that the monkeypox outbreak could turn into another pandemic, local health offices have been flooded with requests for the monkeypox vaccine. According to the Centers for Disease Control and Prevention, there have been just 330 cases here in Georgia as of July 29.
Strong quarterly sales of Pfizer’s Covid-19 products helped offset mixed results from other products, and the drugmaker sees full-year revenue gains being offset by unfavorable currency effects.
The company had said it was in talks with the FDA about seeking early approval, but Wall Street analysts thought the agency would make it wait to apply.
A once-prominent neurologist was found guilty Friday on charges of sexually abusing patients while treating them with pain medications. A New York City jury reached the verdict after deliberating for about three days at the trial of Dr. Ricardo Cruciani. Cruciani, 68, was convicted on 12 criminal counts — one count of predatory sexual assault, one of attempted rape, one of sex abuse, two of rape and seven of criminal sexual acts.
Compared with the earlier Omicron BA.2 subvariant, currently dominant Omicron BA.5 is linked with higher odds of causing a second SARS-COV-2 infection regardless of vaccination status, a study from Portugal suggests. Further, they found, in infected heart muscle cells only the SARS-CoV-2 spike interacted with so-called TLR4 proteins (Toll-like receptor-4) that recognize invaders and trigger inflammatory responses.